Ibuprofen Detailed Renal, GI Warnings Required For Monograph Inclusion
This article was originally published in The Tan Sheet
Executive Summary
Clinical study data and adverse event reports support inclusion of a warning on OTC ibuprofen labeling to alert consumers at risk for developing acute renal failure to consult a doctor, FDA says
You may also be interested in...
McNeil Supports Separate Alcohol, Stomach Bleeding Warnings For Ibuprofen
McNeil Consumer & Specialty Pharmaceuticals endorses separate warnings for alcohol-related stomach bleeding and general gastrointestinal bleeding for 200 mg ibuprofen because the statements would target separate populations, the firm states in Sept. 2 comments to FDA
Ibuprofen ANDA Status Backed By Dr. Reddy’s; Foreign-Sources Defended
Dr. Reddy's Labs claims "there is no need whatsoever" to include ibuprofen 200 mg in the Internal Analgesic, Antipyretic & Anti-rheumatic Drug Products Tentative Final Monograph, in recent comments to FDA
FDA internal analgesics
Comment period on agency's proposal to amend internal analgesics tentative final monograph to include ibuprofen reopened until Sept. 2, FDA says in 1June 4 Federal Register notice. In October, Wyeth requested additional time to evaluate labeling suggestions made during NDAC meeting on internal analgesic products (2"The Tan Sheet" Oct. 28, 2002, In Brief). Firm also said it might conduct consumer research on information relevant to crafting appropriate label. FDA "acknowledges that additional time may be beneficial to fully evaluate and respond to the issues." Agency proposed the amendment in August (3"The Tan Sheet" Aug. 26, 2002, p. 3)...